Role of Drug Therapy for Sustained Ventricular Tachyarrhythmias

Cardiology Clinics

Volumn 26, Issue 3, 2008, Pages 405-418

  Mitchell, L Brent ^a  

^a CALGARY HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DOFETILIDE; ENCAINIDE; FLECAINIDE; IMIPRAMINE; METOPROLOL; MEXILETINE; MORACIZINE; OXPRENOLOL; PHENYTOIN; PINDOLOL; PIRMENOL; PLACEBO; PRACTOLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TIMOLOL; TOCAINIDE; UNINDEXED DRUG; XAMOTEROL;

ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOMYOPATHY; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HAZARD RATIO; HEART ARREST; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; LIVER FUNCTION TEST; LONG TERM CARE; LUNG INFILTRATE; MORTALITY; NAUSEA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; SINUS BRADYCARDIA; SUDDEN DEATH; THERAPY EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CARBAZOLES; DIGOXIN; HEART CONDUCTION SYSTEM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLIDINES; PIPERAZINES; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SOTALOL; TACHYCARDIA, VENTRICULAR;

EID: 44449103129     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.03.004     Document Type: Review

References (109)

1. Zheng Z.J., Croft J.B., Giles W.H., et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104 18 (2001) 2158-2163
2. Bayes de Luna A.B., Coumel P., and Leclercq J.F. Curriculum in cardiology: ambulatory sudden cardiac death; mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117 1 (1989) 151-159
3. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21 24 (2000) 2071-2078
4. Nanthakumar K., Epstein A.E., Kay G.N., et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 11 (2004) 2166-2172
5. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324 12 (1991) 781-788
6. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327 4 (1992) 227-233
7. McAlister F.A., and Teo K.K. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 54 2 (1997) 235-252
8. Friedman P.L., and Stevenson W.G. Proarrhythmia. Am J Cardiol 82 7 Suppl 1 (1998) 50N-58N
9. Dorian P. Antiarrhythmic action of ß-blockers: potential mechanisms. J Cardiovasc Pharmacol Ther 10 Suppl 1 (2005) S15-S22
10. Steinbeck G., Andresen D., Bach P., et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 327 14 (1992) 987-992
11. Lown B., and Graboys T.B. Management of patients with malignant ventricular arrhythmias. Am J Cardiol 39 6 (1977) 910-918
12. Duff H.J., Mitchell L.B., and Wyse D.G. Antiarrhythmic efficacy of propranolol: comparison of low and high serum concentrations. J Am Coll Cardiol 8 4 (1986) 959-965
13. Leclercq J.F., Leenhardt A., Coumel P., et al. Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillators. Eur Heart J 13 9 (1992) 1180-1184
14. Yusuf S., Sleight P., Rossi P.R.F., et al. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction. Circulation 67 6 Pt 2 (1983) I32-I41
15. Rydén L., Arniego R., Arnmar K., et al. A double-blind trial of metoprolol in acute myocardial infarction: effects on ventricular tachycardia. N Engl J Med 308 11 (1983) 614-618
16. Norris R.M., Brown M.A., Clarke E.D., et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 324 8408 (1984) 883-886
17. Lerman B.B., Belardinelli L., West G.A., et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 74 2 (1986) 270-280
18. Sung R.J., Shen E.N., Morady F., et al. Electrophysiologic mechanisms of exercise-induced sustained ventricular tachycardia. Am J Cardiol 51 3 (1983) 525-530
19. Reiter M.J., and Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 4 Suppl 1 (1998) 9I-19I
20. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 5 (1985) 335-371
21. Heidenreich P.A., Lee T.T., and Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 30 1 (1997) 27-34
22. Packer M. Do ß-blockers prolong survival in heart failure only by inhibiting the ß1-receptor? A perspective on the results of the COMET trial. J Card Fail 9 6 (2003) 429-443
23. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362 9377 (2003) 7-13
24. Torp-Pedersen C., Poole-Wilson P.A., Swedberg K., et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure (COMET). Am Heart J 149 2 (2005) 370-376
25. El-Sharif N., and Turitto G. Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?. Pacing Clin Electrophysiol 28 9 (2005) 985-990
26. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 17 (2002) 2194-2199
27. McMurray J., Køber L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 4 (2005) 525-530
28. Anderson J.L., and Prystowski E.N. Sotalol: an important new antiarrhythmic. Am Heart J 137 3 (1999) 388-409
29. Advani S.V., and Singh B.N. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. Drugs 49 5 (1995) 664-679
30. Mounsey J.P., and DiMarco J.P. Dofetilide. Circulation 102 21 (2000) 2665-2670
31. Clemett D., and Markham A. Azimilide. Drugs 59 2 (2000) 271-277
32. Vassallo P., and Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298 11 (2007) 1312-1322
33. Anatasiou-Nana M.I., Gilbert E.M., Miller R.H., et al. Usefulness of d,l sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 67 6 (1991) 511-516
34. Deedwania P.C. Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature beats. Am J Cardiol 65 2 (1990) 43A-50A
35. Lidell C., Rehnquist N., Sjögren A., et al. Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. Am Heart J 109 5 Pt 1 (1985) 970-975
36. Mason J.W., and ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329 7 (1993) 452-458
37. Mason J.W., and ESVEM Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329 7 (1993) 445-451
38. Pacifico A., Hohnloser S.H., Williams J.H., et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 340 24 (1999) 1855-1862
39. Seidl K., Hauer B., Schwick N.G., et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol 82 6 (1998) 744-748
40. Kettering K., Mewis C., Dörnberger V., et al. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 25 11 (2002) 1571-1576
41. Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of ß-blockers, amiodarone plus ß-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA 295 2 (2006) 165-171
42. Barbey J.T., Echt D.S., Thompson K.A., et al. Effect of d-sotalol on ventricular arrhythmias in man. Circulation 72 4 Pt 2 (1985) 170-175
43. Schwartz J., Crocker K., Wynn J., et al. The antiarrhythmic effects of d-sotalol. Am Heart J 114 3 (1987) 539-544
44. Brachmann J., Schols W., Beyer T., et al. Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. Eur Heart J 14 Suppl H (1993) 85-87
45. Echt D.S., Lee J.T., Murray K.T., et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 6 9 (1995) 687-699
46. O'Toole M., O'Neill G., Kluger J., et al. Efficacy and safety of oral dofetilide in patients with an implanted defibrillator: multicenter study. [abstract]. Circulation 100 18 (1999) I-794
47. Boriani G., Biffi M., De Simone N., et al. Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. Pacing Clin Electrophysiol 23 11 Pt 2 (2000) 1935-1938
48. Boriani G., Lubinski A., Capucci A., et al. A multicentre double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 22 23 (2001) 2180-2191
49. Karam R., Marcello S., Brooks R.R., et al. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 81 6 Suppl 1 (1998) 40D-46D
50. Brooks R.R., Drexler A.P., Maynard A.E., et al. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. Proc Soc Exp Biol Med 223 2 (2000) 183-189
51. Singer I., Al-Khalidi H., Niazi I., et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 43 1 (2004) 39-43
52. Dorian P., Borggrefe M., Al-Khalidi H.R., et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110 24 (2004) 3646-3654
53. CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 72 3 (1993) 280-287
54. Julian D.G., Prescott R.J., Jackson F.S., et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 319 8282 (1982) 1142-1147
55. Waldo A.L., Camm A.J., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348 9019 (1996) 7-12
56. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341 12 (1999) 857-865
57. Køber L., Bloch Thomsen P.E., Møller M., et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356 9247 (2000) 2052-2058
58. Camm A.J., Pratt C.M., Schwartz P.J., et al. Mortality in patients after a recent myocardial infarction: a randomized placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109 8 (2004) 990-996
59. Amiodarone Trials Meta-Analysis (ATMA) Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 350 9089 (1997) 1417-1424
60. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 352 3 (2005) 225-237
61. Brendorp B., Pedersen O.D., Torp-Pedersen C., et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 25 12 (2002) 847-865
62. Mason J.W., Swerdlow C.D., and Mitchell L.B. Efficacy of verapamil in chronic, recurrent ventricular tachycardia. Am J Cardiol 51 10 (1983) 1614-1617
63. Belhassen B., Shapira I., Pelleg A., et al. Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECG-electrophysiologic entity. Am Heart J 108 4 Pt 1 (1984) 1034-1037
64. Iwai S., Cantillon D.J., Kim R.J., et al. Right and left ventricular outflow tract tachycardias: evidence for a common electrophysiologic mechanism. J Cardiovasc Electrophysiol 17 10 (2006) 1052-1058
65. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 89 1 (2003) 66-70
66. Grenadier E., Alpan G., Maor N., et al. Polymorphous ventricular tachycardia in acute myocardial infarction. Am J Cardiol 53 9 (1984) 1280-1283
67. Russell R.P. Side effects of calcium channel blockers. Hypertension 11 3 Pt 2 (1988) II42-II44
68. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 83 1 (1991) 52-60
69. Shanes J.G., Minadeo K.N., Moret A., et al. Statin therapy in heart failure: prognostic effects and potential mechanism. Am Heart J 154 4 (2007) 617-623
70. De Sutter J., Tavernier R., De Buyzere M., et al. Lipid-lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 3 (2000) 766-772
71. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 42 1 (2003) 81-87
72. Chiu J.H., Abdelhadi R.H., Chung M.K., et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 4 (2005) 490-491
73. Cholesterol lowering and arrhythmia recurrences after internal defibrillator implantation: the CLARIDI Trial. Available at:. www.clinicalstudyresults.org/documents/company-study_578_0.pdf Accessed January 8, 2008
74. Vyas A.K., Guo H., Moss A.J., et al. Reductions in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 47 4 (2006) 769-773
75. Goldberger J.J., Subacius H., Schaechter A., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 6 (2006) 1228-1233
76. Levantesi G., Scarano M., Marfisi R., et al. Meta-analysis of effects of statin treatment on risk of sudden death. Am J Cardiol 100 11 (2007) 1644-1650
77. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
78. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 11 (2003) 1933-1940
79. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 22 (2007) 2248-2261
80. Altas S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13 8 Suppl S-b (2007) S9-S20
81. Maisel W.H., and Stevenson W.G. Sudden death and the electrophysiological effects of angiotensin-converting enzyme inhibitors. J Card Fail 6 2 (2000) 80-82
82. Cleland J.G., Dargie H.J., Hodsman G.P., et al. Captopril in heart failure: a double-blind controlled trial. Br Heart J 52 5 (1984) 530-535
83. Webster M.W.I., Fitzpatrick A., Nicholls G., et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 56 8 (1985) 566-569
84. Hattori Y., Atsushi S., Hiroaki F., et al. Effects of captopril on ventricular arrhythmias in patients with congestive heart failure. Clin Ther 19 3 (1997) 481-486
85. Bashir Y., Sneddon J.F., O'Nunain S., et al. Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia. Br Heart J 67 5 (1992) 355-360
86. Zakynthinos E., Pierrutsakos C., Daniil Z., et al. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function. Angiology 56 4 (2005) 439-449
87. Barr C.S., Lang C.C., Hanson J., et al. Effects of adding spironolactone to angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 17 (1995) 1259-1265
88. Ramires F.J., Mansur A., Coelho O., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic or to ischemic cardiomyopathy. Am J Cardiol 85 10 (2000) 1207-1211
89. Gao X., Peng L., Adhikari C.M., et al. Spironolactone reduced arrhythmias and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 13 3 (2007) 170-177
90. Garg R., Yusuf S., and Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 18 (1995) 1450-1456
91. Domanski M.J., Exner D.V., Borkowf C.B., et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 33 3 (1999) 598-604
92. Al-Mallah M.H., Tleyjeh I.M., Abdel-Latif A.A., et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function. J Am Coll Cardiol 47 8 (2006) 1576-1583
93. Teo K.K., Mitchell L.B., Pogue J., et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation 110 11 (2004) 1413-1417
94. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 9 (2004) 693-704
95. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 13 (2003) 1893-1906
96. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 9335 (2002) 752-760
97. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 10 (1999) 709-717
98. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
99. Agustí A., Bonet S., Arnau J.M., et al. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction. Drug Saf 26 12 (2003) 895-908
100. Granger C.B., McMurray J.J.V., Yusuf A., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 9386 (2003) 772-776
101. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 18 (2007) 1930-1936
102. Eichhorn E.J., and Gheorghiade M. Digoxin. Prog Cardiovasc Dis 44 4 (2002) 251-266
103. Ruch S.R., Nishio M., and Wasserstrom J.A. Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: role of calcium overload. J Pharmacol Exp Ther 307 1 (2003) 419-428
104. Rocchetti M., Besana A., Mostacciuolo G., et al. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 305 2 (2003) 765-771
105. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259 4 (1988) 539-544
106. DiBianco R., Shabetai R., Kostuk W., et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320 11 (1989) 677-683
107. Gradman A.H., Cunningham M., Harbison M.A., et al. Effects of oral digoxin on ventricular ectopy in relation to left ventricular function. Am J Cardiol 51 5 (1983) 765-769
108. Digitalis Investigator Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 8 (1997) 525-533
109. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 7 (2003) 871-878